Theratechnologies Acquires Commercial Rights to Ibalizumab in the European Union and Four Additional Territories

Mar 06, 2017
PDF Version
Supporting Materials:

Theratechnologies Inc. (Theratechnologies) (TSX: TH) is pleased to announce that it has reached an agreement with TaiMed Biologics, Inc. for the acquisition of the commercial rights to ibalizumab in the European Union, Israel, Norway, Russia and Switzerland.